Giovanni Caforio, Bristol Myers Squibb CEO (Pablo Martinez Monsivais/AP Images)
April 1, 2021 10:01 AM EDT
Pharma
FDA+

Bris­tol My­ers faces $1B+ tax fight af­ter ac­ci­den­tal dis­clo­sure re­veals al­leged off­shore patents scheme — re­port

Kyle Blankenship

The IRS has bat­tled Big Phar­ma for years over off­shore patent trans­fer schemes, which it said have bilked the pub­lic in­ter­est by bil­lions of dol­lars …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

Chro­ma, Nvel­op merge to form nChro­ma Bio, rais­ing $75M to en­ter the clin­ic

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times